Biologics and global burden of asthma: A worldwide portrait and a call for action

Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, rela...

Full description

Saved in:

Bibliographic Details
Published in:	The World Allergy Organization journal Vol. 14; no. 2; p. 100502
Main Authors:	Caminati, M., Morais-Almeida, M., Bleecker, E., Ansotegui, I., Canonica, G.W., Bovo, C., Senna, G.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.02.2021 Elsevier BV World Allergy Organization Elsevier
Subjects:	Allergies Asthma Asthma costs Asthma mortality Biological products Biologics Chronic obstructive pulmonary disease Drugs Health care access Health care expenditures High income Low income groups Monoclonal antibodies Morbidity Mortality Pharmaceutical industry Risk factors Severe asthma Severe asthma prevalence Socioeconomic factors Steroids South Korea United States > US Asia Japan Europe Africa Israel North America Russia Asthma costs Severe asthma Severe asthma prevalence Asthma mortality Biologics
ISSN:	1939-4551, 1939-4551
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, related with the trend of asthma mortality rate, as a marker of the burden of the disease. A decline in the global rate of annual asthma mortality was observed until the 1980s, but overall no further reduction occurred, and the current mortality estimation is 0.19 deaths per 100.000 people. A higher mortality rate has been registered in low and middle-income countries (LMICs), where poor socioeconomic conditions and lack of access to the medical resources are more relevant. The availability of monoclonal antibodies is mainly limited to the developed and high-income countries. Furthermore the overall “asthma management system” in LMICs suffers from a number of restrictions that hamper the widespread availability of biologics besides their costs. The availability of generic drugs in the field of biologics for severe asthma could contribute to facilitate their widespread accessibility. But before that, awareness and expertise regarding severe asthma, and proper tools to assess and manage it, deserve to be shared worldwide. Collaboration projects involving physicians from all the countries through the scientific Academies network and with the support of the Companies active in the field may provide an initial concrete opportunity.
AbstractList	Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, related with the trend of asthma mortality rate, as a marker of the burden of the disease. A decline in the global rate of annual asthma mortality was observed until the 1980s, but overall no further reduction occurred, and the current mortality estimation is 0.19 deaths per 100.000 people. A higher mortality rate has been registered in low and middle-income countries (LMICs), where poor socioeconomic conditions and lack of access to the medical resources are more relevant. The availability of monoclonal antibodies is mainly limited to the developed and high-income countries. Furthermore the overall “asthma management system” in LMICs suffers from a number of restrictions that hamper the widespread availability of biologics besides their costs. The availability of generic drugs in the field of biologics for severe asthma could contribute to facilitate their widespread accessibility. But before that, awareness and expertise regarding severe asthma, and proper tools to assess and manage it, deserve to be shared worldwide. Collaboration projects involving physicians from all the countries through the scientific Academies network and with the support of the Companies active in the field may provide an initial concrete opportunity. Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, related with the trend of asthma mortality rate, as a marker of the burden of the disease.A decline in the global rate of annual asthma mortality was observed until the 1980s, but overall no further reduction occurred, and the current mortality estimation is 0.19 deaths per 100.000 people. A higher mortality rate has been registered in low and middle-income countries (LMICs), where poor socioeconomic conditions and lack of access to the medical resources are more relevant. The availability of monoclonal antibodies is mainly limited to the developed and high-income countries. Furthermore the overall “asthma management system” in LMICs suffers from a number of restrictions that hamper the widespread availability of biologics besides their costs. The availability of generic drugs in the field of biologics for severe asthma could contribute to facilitate their widespread accessibility. But before that, awareness and expertise regarding severe asthma, and proper tools to assess and manage it, deserve to be shared worldwide. Collaboration projects involving physicians from all the countries through the scientific Academies network and with the support of the Companies active in the field may provide an initial concrete opportunity. Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, related with the trend of asthma mortality rate, as a marker of the burden of the disease. A decline in the global rate of annual asthma mortality was observed until the 1980s, but overall no further reduction occurred, and the current mortality estimation is 0.19 deaths per 100.000 people. A higher mortality rate has been registered in low and middle-income countries (LMICs), where poor socioeconomic conditions and lack of access to the medical resources are more relevant. The availability of monoclonal antibodies is mainly limited to the developed and high-income countries. Furthermore the overall "asthma management system" in LMICs suffers from a number of restrictions that hamper the widespread availability of biologics besides their costs. The availability of generic drugs in the field of biologics for severe asthma could contribute to facilitate their widespread accessibility. But before that, awareness and expertise regarding severe asthma, and proper tools to assess and manage it, deserve to be shared worldwide. Collaboration projects involving physicians from all the countries through the scientific Academies network and with the support of the Companies active in the field may provide an initial concrete opportunity.Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, related with the trend of asthma mortality rate, as a marker of the burden of the disease. A decline in the global rate of annual asthma mortality was observed until the 1980s, but overall no further reduction occurred, and the current mortality estimation is 0.19 deaths per 100.000 people. A higher mortality rate has been registered in low and middle-income countries (LMICs), where poor socioeconomic conditions and lack of access to the medical resources are more relevant. The availability of monoclonal antibodies is mainly limited to the developed and high-income countries. Furthermore the overall "asthma management system" in LMICs suffers from a number of restrictions that hamper the widespread availability of biologics besides their costs. The availability of generic drugs in the field of biologics for severe asthma could contribute to facilitate their widespread accessibility. But before that, awareness and expertise regarding severe asthma, and proper tools to assess and manage it, deserve to be shared worldwide. Collaboration projects involving physicians from all the countries through the scientific Academies network and with the support of the Companies active in the field may provide an initial concrete opportunity.
ArticleNumber	100502
Author	Canonica, G.W. Morais-Almeida, M. Ansotegui, I. Bovo, C. Bleecker, E. Senna, G. Caminati, M.
Author_xml	– sequence: 1 givenname: M. surname: Caminati fullname: Caminati, M. email: marco.caminati@univr.it organization: Department of Medicine, University of Verona, Verona, Italy – sequence: 2 givenname: M. surname: Morais-Almeida fullname: Morais-Almeida, M. organization: Allergy Center, CUF Descobertas Hospital, CUF Academic and Research Medical Center, Lisbon, Portugal – sequence: 3 givenname: E. surname: Bleecker fullname: Bleecker, E. organization: Genomics and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, USA – sequence: 4 givenname: I. surname: Ansotegui fullname: Ansotegui, I. organization: Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain – sequence: 5 givenname: G.W. surname: Canonica fullname: Canonica, G.W. organization: Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy – sequence: 6 givenname: C. surname: Bovo fullname: Bovo, C. organization: Medical Direction, University Hospital of Verona, Verona, Italy – sequence: 7 givenname: G. surname: Senna fullname: Senna, G. organization: Department of Medicine, University of Verona, Verona, Italy
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33510833$$D View this record in MEDLINE/PubMed
BookMark	eNqFkktrGzEUhYeS0jzaf1CKoJtu7Oo1Gk0ogTT0EQiUQrsW19IdR64suZqZmPz7yrEbEm-8Go10zod0zzmtjmKKWFVvGZ0yytTHxXQNaZHGKad8s0Vryl9UJ6wV7UTWNTt6sj6uTvt-QamirBavqmMhaka1ECfVz88-hTT3ticQHZmHNINAZmN2GEnqCPTD7RLOySVZpxzc2jskq5SHDH54cACxEALpUiZgB5_i6-plB6HHN7vvWfX765dfV98nNz--XV9d3kysYnSYWIQaqWStai3j0lnoOhQ1QjfTWP67VjagOw6Uo0KumxaldMyyhs061TTirLrecl2ChVllv4R8bxJ487CR8txAHrwNaHjbaOZAtQKtlMoC0por29SoNVrnCutiy1qNsyU6i7E8MDyDPj-J_tbM051pNFWNlgXwYQfI6e-I_WCWvrcYAkRMY2-41EIzJWpapO_3pCXEHMuoDNdSt5TRlhfVu6c3erzK_-SKQG4FNqe-z9g9Shg1m4KYhdkWxGwKYrYFKbbzPZv1A2xy20QaDpl3Y8KS653HbHrrMVp0PqMdyuD9IcCnPYANPvrSoD94f9j-D6907NA
CitedBy_id	crossref_primary_10_1016_j_waojou_2022_100726 crossref_primary_10_1183_13993003_00861_2024 crossref_primary_10_3389_fphar_2025_1631321 crossref_primary_10_2147_JAA_S260604 crossref_primary_10_1002_ppul_27218 crossref_primary_10_1111_all_16569 crossref_primary_10_1016_j_prrv_2025_06_002 crossref_primary_10_1007_s00210_023_02882_y crossref_primary_10_1186_s12887_025_05425_x crossref_primary_10_1016_j_jaip_2024_04_026 crossref_primary_10_2147_JAA_S351720 crossref_primary_10_1016_j_jaip_2022_07_017 crossref_primary_10_1007_s12325_025_03338_w crossref_primary_10_1080_17476348_2022_2153674 crossref_primary_10_1007_s12325_022_02340_w crossref_primary_10_3389_fimmu_2024_1384697 crossref_primary_10_1016_j_jaci_2022_03_024 crossref_primary_10_1183_23120541_00357_2021 crossref_primary_10_1186_s10020_024_00888_7 crossref_primary_10_1002_clt2_12038 crossref_primary_10_1016_j_jaip_2025_04_032 crossref_primary_10_1016_j_pccm_2025_08_002 crossref_primary_10_1016_j_jacig_2023_100188 crossref_primary_10_1080_14712598_2025_2490064 crossref_primary_10_1080_1744666X_2023_2214363 crossref_primary_10_1007_s13346_021_01047_9 crossref_primary_10_1016_j_jaip_2024_03_043 crossref_primary_10_1007_s12325_024_02967_x
Cites_doi	10.1016/j.jaci.2012.01.039 10.1097/ACI.0000000000000360 10.1111/cea.13378 10.1164/rccm.201904-0903SO 10.1016/j.waojou.2020.100464 10.1097/MCP.0b013e3282f1982d 10.1080/20018525.2017.1334508 10.1016/S0140-6736(17)31448-4 10.1016/j.jaip.2018.12.029 10.1586/17476348.2016.1114417 10.1016/j.waojou.2019.100032 10.1186/s12931-019-1255-z 10.1056/NEJM199412083312302 10.1186/s40733-016-0029-3 10.1186/1471-2458-12-204 10.1016/j.jaci.2014.12.1871 10.1186/s40413-016-0129-9 10.1007/s43441-019-00101-6
ContentType	Journal Article
Copyright	2020 The Authors 2020 The Authors. 2020. The Authors 2020 The Authors 2020
Copyright_xml	– notice: 2020 The Authors – notice: 2020 The Authors. – notice: 2020. The Authors – notice: 2020 The Authors 2020
DBID	6I. AAFTH AAYXX CITATION NPM K9. NAPCQ 7X8 5PM DOA
DOI	10.1016/j.waojou.2020.100502
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic
DatabaseTitleList	PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: 开放获取期刊（Open Access Journals） url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1939-4551
ExternalDocumentID	oai_doaj_org_article_29781da693ec446cae0526c75e88ecdd PMC7806784 33510833 10_1016_j_waojou_2020_100502 S1939455120304051
Genre	Journal Article
GeographicLocations	South Korea United States--US Asia Japan Europe Africa Israel North America Russia
GeographicLocations_xml	– name: Israel – name: Asia – name: South Korea – name: Japan – name: Russia – name: Africa – name: United States--US – name: North America – name: Europe
GroupedDBID	--- .1- .FO 08G 0R~ 123 4.4 53G 5VS 7RV 7X7 8C1 8FI 8FJ AAEDW AAKAS AAKDD AALRI AAXUO AAYWO ABMAC ABUWG ACGFS ACIHN ACVFH ADBBV ADBIZ ADCNI ADRAZ ADUKV ADVLN ADZCM AEAQA AEUPX AEXQZ AFJKZ AFKRA AFPUW AFRHN AFTJW AFTRI AHBYD AHMBA AHSBF AHYZX AIGII AITUG AIZYK AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ AOIJS APXCP AQUVI ASPBG AVWKF BCNDV BENPR BFQNJ BKEYQ BMC BPHCQ BVXVI C6C CCPQU CS3 EBS EJD EX3 FDB FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ IAO IHR IPNFZ ITC KD2 KQ8 M0T M41 M48 M~E NAPCQ NTWIH O9- OK1 OVD P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC RBZ RIG RNS ROL RPM RSV SOJ SSZ TEORI UKHRP V2I W3M WOQ WOW Z5R -A0 0SF 3V. 6I. AACTN AAFTH ABVAZ ACRMQ ADINQ AFGXO AFNRJ AWKKM C24 IHW NCXOZ AAYXX AFFHD CITATION ALIPV NPM K9. 7X8 5PM
ID	FETCH-LOGICAL-c610t-cea5e041969c124dcaffe35eafb8e24df947a8f2a02e6e2879e44d1c171bf6773
IEDL.DBID	DOA
ISICitedReferencesCount	33
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000632884100006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1939-4551
IngestDate	Fri Oct 03 12:45:27 EDT 2025 Tue Sep 30 16:55:59 EDT 2025 Thu Sep 04 19:07:09 EDT 2025 Tue Oct 07 06:37:57 EDT 2025 Thu Jan 02 22:58:52 EST 2025 Wed Nov 05 20:47:11 EST 2025 Tue Nov 18 22:16:31 EST 2025 Fri Feb 23 02:45:42 EST 2024 Tue Oct 14 19:34:22 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	Asthma costs Severe asthma Severe asthma prevalence Asthma mortality Biologics
Language	English
License	This is an open access article under the CC BY-NC-ND license. 2020 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c610t-cea5e041969c124dcaffe35eafb8e24df947a8f2a02e6e2879e44d1c171bf6773
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://doaj.org/article/29781da693ec446cae0526c75e88ecdd
PMID	33510833
PQID	2848901092
PQPubID	2040184
ParticipantIDs	doaj_primary_oai_doaj_org_article_29781da693ec446cae0526c75e88ecdd pubmedcentral_primary_oai_pubmedcentral_nih_gov_7806784 proquest_miscellaneous_2483816350 proquest_journals_2848901092 pubmed_primary_33510833 crossref_primary_10_1016_j_waojou_2020_100502 crossref_citationtrail_10_1016_j_waojou_2020_100502 elsevier_sciencedirect_doi_10_1016_j_waojou_2020_100502 elsevier_clinicalkey_doi_10_1016_j_waojou_2020_100502
PublicationCentury	2000
PublicationDate	2021-02-01
PublicationDateYYYYMMDD	2021-02-01
PublicationDate_xml	– month: 02 year: 2021 text: 2021-02-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Milwaukee
PublicationTitle	The World Allergy Organization journal
PublicationTitleAlternate	World Allergy Organ J
PublicationYear	2021
Publisher	Elsevier Inc Elsevier BV World Allergy Organization Elsevier
Publisher_xml	– name: Elsevier Inc – name: Elsevier BV – name: World Allergy Organization – name: Elsevier
References	Nunes, Pereira, Morais-Almeida (bib15) 2017; 3 Lundbäck, Backman, Lötvall, Rönmark (bib2) 2016; 10 Backman, Hedman, Stridsman (bib6) 2017; 4 Brakema, Tabyshova, van der Kleij (bib11) 2019; 20 Backman, Jansson, Stridsman (bib4) 2019; 49 Vianello, Caminati, Crivellaro (bib7) 2016; 9 Bleecker, Menzies-Gow, Price (bib18) 2020; 201 Canonica, Blasi, Paggiaro (bib20) 2020 Sep 20; 13 (bib12) 16th August 2020 To, Stanojevic, Moores (bib1) 2012; 12 Restrepo, Peters (bib9) 2008; 14 Ivanova, Bergman, Birbaum, Colige, Silverman, McLaurin (bib17) 2012; 129 Arnaud, Caroline, Juliette, Malik, Elsa (bib19) 2019; 7 Cruz, Stelmach, Ponte (bib10) 2017; 17 Vianello, Caminati, Andretta (bib5) 2019; 12 Fajt, Wenzel (bib8) 2015; 135 Lang, Polansky (bib14) 1994; 331 O'Byrne, Fabbri, Pavord, Papi, Petruzzelli, Lange (bib16) 2019; 18 Abhishek, Muthusamy, Sushma, Ramesh, Suresh (bib21) 2020 May; 54 Ebmeier, Thayabaran, Braithwaite, Bénamara, Weatherall, Beasley (bib3) 2017; 390 Sinharoy, Mitra, Mondal (bib13) 2018; 2018 O'Byrne (10.1016/j.waojou.2020.100502_bib16) 2019; 18 Canonica (10.1016/j.waojou.2020.100502_bib20) 2020; 13 Arnaud (10.1016/j.waojou.2020.100502_bib19) 2019; 7 Backman (10.1016/j.waojou.2020.100502_bib6) 2017; 4 Cruz (10.1016/j.waojou.2020.100502_bib10) 2017; 17 Fajt (10.1016/j.waojou.2020.100502_bib8) 2015; 135 Sinharoy (10.1016/j.waojou.2020.100502_bib13) 2018; 2018 Ivanova (10.1016/j.waojou.2020.100502_bib17) 2012; 129 To (10.1016/j.waojou.2020.100502_bib1) 2012; 12 Restrepo (10.1016/j.waojou.2020.100502_bib9) 2008; 14 Abhishek (10.1016/j.waojou.2020.100502_bib21) 2020; 54 Vianello (10.1016/j.waojou.2020.100502_bib7) 2016; 9 Lang (10.1016/j.waojou.2020.100502_bib14) 1994; 331 Bleecker (10.1016/j.waojou.2020.100502_bib18) 2020; 201 Lundbäck (10.1016/j.waojou.2020.100502_bib2) 2016; 10 Vianello (10.1016/j.waojou.2020.100502_bib5) 2019; 12 Brakema (10.1016/j.waojou.2020.100502_bib11) 2019; 20 Nunes (10.1016/j.waojou.2020.100502_bib15) 2017; 3 Ebmeier (10.1016/j.waojou.2020.100502_bib3) 2017; 390 Backman (10.1016/j.waojou.2020.100502_bib4) 2019; 49
References_xml	– volume: 12 start-page: 204 year: 2012 ident: bib1 article-title: Global asthma prevalence in adults: findings from the cross-sectional world health survey publication-title: BMC Publ Health – volume: 49 start-page: 819 year: 2019 end-page: 882 ident: bib4 article-title: Severe asthma-A population study perspective publication-title: Clin Exp Allergy – volume: 2018 start-page: 93895701 year: 2018 ident: bib13 article-title: Socioeconomic and environmental predictors of asthma-related mortality publication-title: J Environ Public Health – volume: 3 start-page: 1 year: 2017 ident: bib15 article-title: Asthma costs and social impact publication-title: Asthma Res Pract – volume: 7 start-page: 1477 year: 2019 end-page: 1487 ident: bib19 article-title: The burden of severe asthma in France: a case control study using a medical claims database publication-title: J Allergy Clin Immunol Pract – volume: 13 start-page: 100464 year: 2020 Sep 20 ident: bib20 article-title: SANI (severe asthma network Italy). Oral CorticoSteroid sparing with biologics in severe asthma: a remark of the severe asthma network in Italy (SANI) publication-title: World Allergy Organ J – volume: 390 start-page: 935 year: 2017 end-page: 945 ident: bib3 article-title: Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012) publication-title: Lancet – volume: 9 start-page: 42 year: 2016 ident: bib7 article-title: Fatal asthma; is it still an epidemic? publication-title: World Allergy Organ J – volume: 10 start-page: 39 year: 2016 end-page: 51 ident: bib2 article-title: Is asthma prevalence still increasing? publication-title: Expet Rev Respir Med – volume: 20 start-page: 291 year: 2019 ident: bib11 article-title: The socioeconomic burden of chronic lung disease in low-resource settings across the globe - an observational FRESH AIR study publication-title: Respir Res – volume: 14 start-page: 13 year: 2008 end-page: 23 ident: bib9 article-title: Near-fatal asthma: recognition and management publication-title: Curr Opin Pulm Med – volume: 17 start-page: 188 year: 2017 end-page: 193 ident: bib10 article-title: Asthma prevalence and severity in low-resource communities publication-title: Curr Opin Allergy Clin Immunol – volume: 331 start-page: 1542 year: 1994 end-page: 1547 ident: bib14 article-title: Patterns of asthma mortality in Philadelphia from 1969 to 1991 publication-title: N Engl J Med – volume: 18 start-page: 54 year: 2019 ident: bib16 article-title: Asthma progression and mortality: the role of inhaled corticosteroids publication-title: Eur Respir J – volume: 201 start-page: 276 year: 2020 end-page: 293 ident: bib18 article-title: Tran TN systematic literature review of systemic corticosteroid use for asthma management publication-title: Am J Respir Crit Care Med – year: 16th August 2020 ident: bib12 article-title: Asthma surveillance data, centers for disease control and prevention – volume: 129 start-page: 1229 year: 2012 end-page: 1235 ident: bib17 article-title: Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma publication-title: J Allergy Clin Immunol – volume: 12 start-page: 100032 year: 2019 ident: bib5 article-title: Prevalence of severe asthma according to the drug regulatory agency perspective: an Italian experience publication-title: World Allergy Organ J – volume: 54 start-page: 667 year: 2020 May end-page: 680 ident: bib21 article-title: Postmarketing safety of biosimilars: current status, challenges, and opportunities in the spontaneous reporting system publication-title: Ther Innov Regul Sci – volume: 135 start-page: 299 year: 2015 end-page: 310 ident: bib8 article-title: Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care publication-title: J Allergy Clin Immunol – volume: 4 start-page: 1334508 year: 2017 ident: bib6 article-title: A population-based cohort of adults with asthma: mortality and participation in a long-term follow-up publication-title: Eur Clin Respir J – volume: 129 start-page: 1229 year: 2012 ident: 10.1016/j.waojou.2020.100502_bib17 article-title: Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2012.01.039 – volume: 17 start-page: 188 year: 2017 ident: 10.1016/j.waojou.2020.100502_bib10 article-title: Asthma prevalence and severity in low-resource communities publication-title: Curr Opin Allergy Clin Immunol doi: 10.1097/ACI.0000000000000360 – volume: 2018 start-page: 93895701 year: 2018 ident: 10.1016/j.waojou.2020.100502_bib13 article-title: Socioeconomic and environmental predictors of asthma-related mortality publication-title: J Environ Public Health – volume: 18 start-page: 54 year: 2019 ident: 10.1016/j.waojou.2020.100502_bib16 article-title: Asthma progression and mortality: the role of inhaled corticosteroids publication-title: Eur Respir J – volume: 49 start-page: 819 year: 2019 ident: 10.1016/j.waojou.2020.100502_bib4 article-title: Severe asthma-A population study perspective publication-title: Clin Exp Allergy doi: 10.1111/cea.13378 – volume: 201 start-page: 276 year: 2020 ident: 10.1016/j.waojou.2020.100502_bib18 article-title: Tran TN systematic literature review of systemic corticosteroid use for asthma management publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201904-0903SO – volume: 13 start-page: 100464 issue: 10 year: 2020 ident: 10.1016/j.waojou.2020.100502_bib20 article-title: SANI (severe asthma network Italy). Oral CorticoSteroid sparing with biologics in severe asthma: a remark of the severe asthma network in Italy (SANI) publication-title: World Allergy Organ J doi: 10.1016/j.waojou.2020.100464 – volume: 14 start-page: 13 year: 2008 ident: 10.1016/j.waojou.2020.100502_bib9 article-title: Near-fatal asthma: recognition and management publication-title: Curr Opin Pulm Med doi: 10.1097/MCP.0b013e3282f1982d – volume: 4 start-page: 1334508 year: 2017 ident: 10.1016/j.waojou.2020.100502_bib6 article-title: A population-based cohort of adults with asthma: mortality and participation in a long-term follow-up publication-title: Eur Clin Respir J doi: 10.1080/20018525.2017.1334508 – volume: 390 start-page: 935 year: 2017 ident: 10.1016/j.waojou.2020.100502_bib3 article-title: Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012) publication-title: Lancet doi: 10.1016/S0140-6736(17)31448-4 – volume: 7 start-page: 1477 year: 2019 ident: 10.1016/j.waojou.2020.100502_bib19 article-title: The burden of severe asthma in France: a case control study using a medical claims database publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2018.12.029 – volume: 10 start-page: 39 year: 2016 ident: 10.1016/j.waojou.2020.100502_bib2 article-title: Is asthma prevalence still increasing? publication-title: Expet Rev Respir Med doi: 10.1586/17476348.2016.1114417 – volume: 12 start-page: 100032 year: 2019 ident: 10.1016/j.waojou.2020.100502_bib5 article-title: Prevalence of severe asthma according to the drug regulatory agency perspective: an Italian experience publication-title: World Allergy Organ J doi: 10.1016/j.waojou.2019.100032 – volume: 20 start-page: 291 issue: 1 year: 2019 ident: 10.1016/j.waojou.2020.100502_bib11 article-title: The socioeconomic burden of chronic lung disease in low-resource settings across the globe - an observational FRESH AIR study publication-title: Respir Res doi: 10.1186/s12931-019-1255-z – volume: 331 start-page: 1542 year: 1994 ident: 10.1016/j.waojou.2020.100502_bib14 article-title: Patterns of asthma mortality in Philadelphia from 1969 to 1991 publication-title: N Engl J Med doi: 10.1056/NEJM199412083312302 – volume: 3 start-page: 1 year: 2017 ident: 10.1016/j.waojou.2020.100502_bib15 article-title: Asthma costs and social impact publication-title: Asthma Res Pract doi: 10.1186/s40733-016-0029-3 – volume: 12 start-page: 204 year: 2012 ident: 10.1016/j.waojou.2020.100502_bib1 article-title: Global asthma prevalence in adults: findings from the cross-sectional world health survey publication-title: BMC Publ Health doi: 10.1186/1471-2458-12-204 – volume: 135 start-page: 299 year: 2015 ident: 10.1016/j.waojou.2020.100502_bib8 article-title: Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.12.1871 – volume: 9 start-page: 42 year: 2016 ident: 10.1016/j.waojou.2020.100502_bib7 article-title: Fatal asthma; is it still an epidemic? publication-title: World Allergy Organ J doi: 10.1186/s40413-016-0129-9 – volume: 54 start-page: 667 issue: 3 year: 2020 ident: 10.1016/j.waojou.2020.100502_bib21 article-title: Postmarketing safety of biosimilars: current status, challenges, and opportunities in the spontaneous reporting system publication-title: Ther Innov Regul Sci doi: 10.1007/s43441-019-00101-6
SSID	ssj0060153
Score	2.363011
Snippet	Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the...
SourceID	doaj pubmedcentral proquest pubmed crossref elsevier
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	100502
SubjectTerms	Allergies Asthma Asthma costs Asthma mortality Biological products Biologics Chronic obstructive pulmonary disease Drugs Health care access Health care expenditures High income Low income groups Monoclonal antibodies Morbidity Mortality Pharmaceutical industry Risk factors Severe asthma Severe asthma prevalence Socioeconomic factors Steroids
Title	Biologics and global burden of asthma: A worldwide portrait and a call for action
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1939455120304051 https://dx.doi.org/10.1016/j.waojou.2020.100502 https://www.ncbi.nlm.nih.gov/pubmed/33510833 https://www.proquest.com/docview/2848901092 https://www.proquest.com/docview/2483816350 https://pubmed.ncbi.nlm.nih.gov/PMC7806784 https://doaj.org/article/29781da693ec446cae0526c75e88ecdd
Volume	14
WOSCitedRecordID	wos000632884100006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1939-4551 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0060153 issn: 1939-4551 databaseCode: RBZ dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: 开放获取期刊（Open Access Journals） customDbUrl: eissn: 1939-4551 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0060153 issn: 1939-4551 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources (ISSN International Center) customDbUrl: eissn: 1939-4551 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0060153 issn: 1939-4551 databaseCode: M~E dateStart: 20080101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgQogL4puFUhmJa0QSx7HNraBWHGgFEkh7syb2RA1qs2g3pbf-9o7tJOrCYTlwWSlrO-uMJzNv1jPPjL3TaMCQq8tcXjRZJdFkDcGMDIrGgZdeVxB5Zr-o01O9XJqvt476CjlhiR44Ce59GUiZPNRGoKPQxQEGhhKnJGqNzvtgfQn1TMFUssEUZUT-SUInhiYgi6loLmZ2XcGKFopiwzImCcjxL5XJKUXu_i3f9Df2_DOF8pZPOn7EHo5gkh-mh3jM7mD_hN0_GbfLn7Jv6aTJzm049J4n8g_exMoFvmo5bIazC_jAD3kkTr3qPPKAx9fQDXEEcFrCc07AlqcCiGfsx_HR90-fs_EMhcwRMBoyhyAxrwIJjiNX7h20LQqJ0DYa6bo1lQLdlpCXWCOFTwaryheuUEXT1kqJ52yvX_X4kvHclyrUKtSqDbuhNYiC4ArmpZNNi-gWTExCtG4kGA8TPrdTJtlPm0Rvg-htEv2CZfOoX4lgY0f_j2F95r6BHjt-QUpjR6Wxu5RmweS0unaqQCWbSTfqdvy4mseNCCUhj38YuT8pkR2txMYSNNAhPcZQ89u5md7vsGkDPa4uqU-lw96ukPmCvUg6Nz-7EGRRtRA0rS1t3BLOdkvfnUUOcaUDTKle_Q9pvmYPypDpE3PZ99nesL7EN-ye-z10m_UBu6uW-iC-nvR5cn10A_ocPss
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biologics+and+global+burden+of+asthma%3A+A+worldwide+portrait+and+a+call+for+action&rft.jtitle=The+World+Allergy+Organization+journal&rft.au=Caminati%2C+M&rft.au=Morais-Almeida%2C+M&rft.au=Bleecker%2C+E&rft.au=Ansotegui%2C+I&rft.date=2021-02-01&rft.pub=Elsevier+BV&rft.eissn=1939-4551&rft.volume=14&rft.issue=2&rft_id=info:doi/10.1016%2Fj.waojou.2020.100502&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1939-4551&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1939-4551&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1939-4551&client=summon